XSHG
603456
Market cap2.15bUSD
Oct 09, Last price
16.31CNY
1D
-0.24%
1Q
10.43%
Jan 2017
36.14%
IPO
140.21%
Name
Zhejiang Jiuzhou Pharmaceutical Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Zhejiang Jiuzhou Pharmaceutical Co., Ltd, a company established in 1973 and operating from its headquarters in Taizhou, China, specializes in the production and global supply of active pharmaceutical ingredients (APIs) and their chemical precursors. Its extensive product catalog includes APIs designed for a wide range of therapeutic applications, encompassing treatments for central nervous system disorders (such as anti-depressants and Parkinson's disease), various infectious ailments (including antiviral, general anti-infection, and specific respiratory anti-infection agents), diabetes management, non-steroidal drugs, oncological therapies, Hepatitis C, and cardiovascular conditions. Furthermore, beyond its pharmaceutical focus, the company also furnishes specialized asymmetric catalysts and crucial materials utilized in lithium-ion batteries.
Key people
General Manager · since 2016
Daqing Che
Deputy General Manager
Zulin Jiang
Deputy General Manager
Yuanqiang Li
Deputy General Manager · since 2016
Huilu Lin
Deputy General Manager, Secretary of the Board
Yijiang Mei
Deputy General Manager · since 2016
Lirong Hua
Chairman of the Board · since 2016
Wenze Li
Director · since 2017
Headquarters & legal address
浙江省台州市椒江区外沙工业区
台州市, ZJ 310000
CN
台州市, ZJ 310000
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||